D-Nome Pvt Ltd

D-Nome Pvt Ltd is an India-based health-tech company focused on molecular diagnostics, utilizing innovative cell-free synthetic biotechnology to provide rapid and accurate testing solutions. D-Nome Pvt Ltd operates in the health-tech sector, specializing in molecular diagnostics. Founded in 2021 and headquartered in Hyderabad, India, the company has undergone no reported pivots in its business strategy. The founders, Divya S and Sujoy D, have experience in the industry.

As of December 23, 2022, D-Nome raised INR 122. 09 million in SEED funding, led by Ankur Capital, alongside other investors including 3i Partners, 8X Ventures, Campus Fund, and Seeders Venture Capital. The total amount raised by the company is INR 122. 09 million, with a current valuation of INR 518.

438 million. D-Nome Pvt Ltd is a pioneering deep-tech start-up specializing in molecular diagnostics through its innovative cell-free synthetic biotechnology. Its flagship product, the D-LAMP enzyme mix, enables rapid and accurate diagnostics for infectious disease detection and genetic analysis. The company's technologies aim to enhance accessibility to molecular diagnostics, catering primarily to healthcare providers, research institutions, and diagnostics laboratories.

D-Nome markets its products in regions such as Southeast Asia, Africa, and parts of Europe, focusing on the demand for affordable diagnostic solutions. In the most recent fiscal year, D-Nome Pvt Ltd reported revenue of INR 13,294. 7 million and an EBITDA of INR -48,606 million. The company generates revenue through strategic partnerships, collaborations, and direct sales of its diagnostic products, focusing on B2B agreements with healthcare institutions and diagnostics laboratories, which allow volume-based pricing for their enzyme mixes and technologies.

D-Nome Pvt Ltd plans to utilize its recent SEED funding of INR 122. 09 million, raised in December 2022, to accelerate its growth strategy. The company aims to introduce new diagnostic products designed to expand its offerings and is considering entry into new markets across Southeast Asia and Africa by 2024. This strategic expansion is intended to enhance its market presence and meet the increasing demand for efficient diagnostic solutions.